An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1